ID   TOV-1946
AC   CVCL_4062
SY   TOV1946
DR   cancercelllines; CVCL_4062
DR   Cosmic; 1122314
DR   GEO; GSM2475007
DR   Wikidata; Q54972807
RX   PubMed=18507860;
RX   PubMed=22585861;
RX   PubMed=22931248;
RX   PubMed=28273451;
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=TOV-1946
CC   Doubling time: 1.3 +- 0.4 days (PubMed=18507860); 2.2 +- 0.26 days (PubMed=22931248).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=18507860; PubMed=22931248; PubMed=28273451).
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson A.-M.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12
ST   D16S539: 11
ST   D21S11: 30
ST   D5S818: 11
ST   D7S820: 11,12
ST   TH01: 9,9.3
ST   TPOX: 8,10
ST   vWA: 14,15
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_4375 ! OV-1946
SX   Female
AG   75Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=18507860; DOI=10.1186/1471-2407-8-152;
RA   Ouellet V., Zietarska M., Portelance L., Lafontaine J., Madore J.,
RA   Puiffe M.-L., Arcand S.L., Shen Z., Hebert J., Tonin P.N.,
RA   Provencher D.M., Mes-Masson A.-M.;
RT   "Characterization of three new serous epithelial ovarian cancer cell
RT   lines.";
RL   BMC Cancer 8:152.1-152.18(2008).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22931248; DOI=10.1186/1471-2407-12-379;
RA   Letourneau I.J., Quinn M.C.J., Wang L.-L., Portelance L., Caceres K.Y.,
RA   Cyr L., Delvoye N., Meunier L., de Ladurantaye M., Shen Z.,
RA   Arcand S.L., Tonin P.N., Provencher D.M., Mes-Masson A.-M.;
RT   "Derivation and characterization of matched cell lines from primary
RT   and recurrent serous ovarian cancer.";
RL   BMC Cancer 12:379.1-379.16(2012).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A.,
RA   Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J.,
RA   Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//